, Volume 62, Issue 11, pp 1686–1686 | Cite as

Fondaparinux Sodium

A Viewpoint by Alexander G. G. Turpie
  • Alexander G. G. Turpie
Adis New Drug Profile Guest Commentary


  1. 1.
    Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/-ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000 Nov 28; 102: 2726–31CrossRefGoogle Scholar
  2. 2.
    Turpie AGG, Gallus AS, Hoek JA, et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001 Mar 1; 344: 619–25PubMedCrossRefGoogle Scholar
  3. 3.
    Coussement PK, Bassand J-P, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001 Sep; 22(18): 1716–24PubMedCrossRefGoogle Scholar
  4. 4.
    Lassen MR, Eriksson BI, Turpie AGG, et al. Comparison of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR901107A with low molecular weight heparin (LMWH) in the prophylaxis of venous thromboembolism (VTE) following major orthopedic surgery [abstract 254]. International Surgical Week — ISW 2001 — 39th World Congress of Surgery Centennial Congress; 2001 Aug 26; Brussels, 64Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Alexander G. G. Turpie
    • 1
  1. 1.Hamilton Health Sciences —General DivisionHamiltonCanada

Personalised recommendations